Axsome Therapeutics, Inc.

As of June 30, 2026, Axsome Therapeutics, Inc. carries a market capitalization of 11.08B, placing it among publicly traded companies globally. Its enterprise value stands at 11.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Axsome Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Axsome Therapeutics, Inc. has 52.30M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 15.87, and the price-to-book ratio stands at 151.99.

These figures are as of June 30, 2026. The EV/Sales ratio of 16.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 11.00B versus a market cap of 11.08B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Axsome Therapeutics, Inc. maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 269.73, indicating elevated leverage, while an interest coverage ratio of -35.11 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Axsome Therapeutics, Inc. posted a negative return on equity (ROE) of -245.10, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.35, reflecting losses generated across the asset base. The company generates approximately 786,270.50 in revenue per employee across its workforce of 864.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.87 indicates how many times Axsome Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Axsome Therapeutics, Inc. recorded 488,417.40 in income tax expense. The company reported a pretax loss of -167.26M and -167.75M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 167.44, while the 200-day moving average is 173.12.

Over the twelve months ended June 30, 2026, Axsome Therapeutics, Inc. generated 679.73M in revenue and converted that into -167.75M in net income, yielding earnings per share of -3.29. EBITDA reached -154.17M, while operating income came in at -160.06M.

As of June 30, 2026, Axsome Therapeutics, Inc. holds 279.96M in cash and equivalents against 196.67M in total debt, resulting in a net debt position of -115.45M. Total book value stands at 72.92M, with working capital of 171.67M providing operational flexibility.

Axsome Therapeutics, Inc. produced -62.37M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -612,710.00 in capital expenditures, free cash flow totaled -62.99M - equivalent to -1.24 per share.

Over the twelve months ended June 30, 2026, Axsome Therapeutics, Inc. posted a gross margin of 93.24, reflecting its pricing power and cost economics. The operating margin of -23.55 and net profit margin of -24.68 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.58: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.70, meaning Axsome Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Axsome Therapeutics, Inc. has an Altman Z-Score of 8.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.